Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3287425 | 0.87 | HCAR1 (0.39) | ALDH1A1HCAR1SLC22A12SMN1; SMN2MAPK1 | |
| SCHEMBL3285904 | 0.84 | HCAR1 (0.37) | ALDH1A1HCAR1SLC22A12SMN1; SMN2MAPK1 | |
| SCHEMBL3286170 | 0.81 | ALDH1A1 (0.37) | ALDH1A1HCAR1SLC22A12SMN1; SMN2MAPK1 | |
| SCHEMBL3285313 | 0.80 | MAPT (0.36) | ALDH1A1HCAR1SLC22A12SMN1; SMN2MAPK1 | |
| SCHEMBL3285303 | 0.80 | ALDH1A1 (0.41) | ALDH1A1HCAR1SLC22A12SMN1; SMN2MAPK1 | |
| SCHEMBL3288323 | 0.78 | HCAR1 (0.39) | ALDH1A1HCAR1SMN1; SMN2MAPK1MEN1 | |
| SCHEMBL26611054 | 0.78 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL3292421 | 0.78 | PTGS2 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL13325334 | 0.75 | ALDH1A1 (0.43) | ALDH1A1HCAR1SMN1; SMN2MAPK1MEN1 | |
| SCHEMBL3290383 | 0.74 | MEN1 (0.37) | ALDH1A1HCAR1SMN1; SMN2MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1761531-A1 | IMIDAZOLE VARIANTS AS MODULATORS OF GABA RECEPTOR FOR THE TREATMENT OF GI DISORDERS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006001750-A1 | IMIDAZOLE VARIANTS AS MODULATORS OF GABA RECEPTOR FOR THE TREATMENT OF GI DISORDERS | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | GABRB1, GABBR2, GABBR1 | ALDH1A1 1225/4885HCAR1 181/4885SLC22A12 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.